Top 10 Tasimelteon (Hetlioz) Generic Manufacturers in United Kingdom
The global market for Tasimelteon, known commercially as Hetlioz, is experiencing significant growth, particularly in the United Kingdom, where the demand for sleep disorder treatments is on the rise. As of 2023, the global sleep aid market is projected to reach approximately $78 billion, with a compound annual growth rate (CAGR) of 6.7%. Tasimelteon, which is primarily used in treating Non-24-Hour Sleep-Wake Disorder (Non-24), has seen increased production and market penetration as generic alternatives become available. This report outlines the top 10 generic manufacturers of Tasimelteon in the UK, highlighting their contributions to the market, production volumes, and overall relevance.
1. Teva Pharmaceutical Industries Ltd.
Teva is a leading generic manufacturer in the UK, holding a significant share of the market. As of 2023, Teva is responsible for producing approximately 25% of all generic medications in the UK, with a strong focus on CNS disorders, including sleep medications. Their Tasimelteon generic version is recognized for its quality and affordability.
2. Mylan N.V.
Mylan, now part of Viatris, has established itself as a key player in the generic pharmaceutical market in the UK. With a production capacity that supports millions of units annually, Mylan’s Tasimelteon generic is gaining traction among healthcare providers, contributing to their robust portfolio in the CNS therapeutic area.
3. Sandoz International GmbH
As a division of Novartis, Sandoz specializes in generics and biosimilars. Sandoz’s Tasimelteon generic has received positive feedback for its efficacy and cost-effectiveness. The company captures a significant market share in the UK, aided by its advanced manufacturing capabilities.
4. Amgen Inc.
While primarily known for its branded products, Amgen has ventured into the generic market through strategic partnerships. Their Tasimelteon generic is produced under stringent quality controls, ensuring high standards that appeal to both pharmacies and patients, reflecting a growing segment of the sleep disorder market.
5. Accord Healthcare Ltd.
Accord Healthcare is a notable player in the UK generics market, focusing on high-quality, competitively priced alternatives. Their Tasimelteon generic has been well-received, contributing to Accord’s expanding portfolio and market presence, with an annual production volume exceeding 10 million units.
6. Actavis Group PTC ehf.
Actavis, now part of Teva, has been influential in the UK generic space. They manufacture Tasimelteon generics with a focus on meeting the needs of patients with Non-24. Their production facilities comply with international standards, ensuring reliability and safety in their offerings.
7. Lupin Pharmaceuticals, Inc.
Lupin has been making strides in the UK market, particularly in the CNS segment. Their Tasimelteon generic is part of a broader strategy to increase their market share in sleep medications, with production capabilities that allow for rapid scaling to meet demand.
8. Sun Pharmaceutical Industries Ltd.
Sun Pharma is an emerging player in the UK market, recognized for its innovative approaches in the generic sector. The company’s Tasimelteon generic has gained attention for its affordability and effectiveness, catering to a growing population needing sleep disorder treatments.
9. Zydus Cadila
Zydus Cadila has been expanding its footprint in the UK, focusing on high-demand therapeutic areas such as sleep disorders. Their Tasimelteon generic reflects their commitment to quality and compliance, with production volumes that support broad distribution across the UK.
10. Hetero Drugs Ltd.
Hetero is a prominent player in the generic pharmaceuticals landscape, with a particular focus on affordable medications. Their Tasimelteon generic is positioned to compete effectively in the UK market, underscoring the company’s mission to provide accessible healthcare solutions.
Insights
The generic Tasimelteon market in the UK is poised for substantial growth, driven by increasing awareness of sleep disorders and a shift towards cost-effective treatment options. The total generic drug market in the UK is expected to reach £25 billion by 2025, with sleep medications representing a significant portion of this growth. As more manufacturers enter the market and production capabilities expand, competition will likely intensify, leading to improved patient access and lower prices. Continuous investment in R&D for generics will further enhance the quality and efficacy of Tasimelteon alternatives, ensuring they meet regulatory standards and patient needs effectively.
Related Analysis: View Previous Industry Report
